TRT(SH:600085) Cai Jing Wang·2025-12-09 03:19Core Viewpoint - Tongrentang (600085) has received approval from the Canadian Ministry of Health for the product license of its product, Shenling Baizhu Powder, which indicates a significant step in its international expansion efforts [1] Group 1: Product Development and Approval - The product Shenling Baizhu Powder has been successfully registered with a cumulative R&D investment of approximately 2.29 million yuan (unaudited) [1] - The primary indications for Shenling Baizhu Powder include alleviating symptoms such as spleen and stomach weakness, reduced appetite, diarrhea, shortness of breath, cough, and fatigue [1] Group 2: Market Entry Challenges - Despite obtaining the product license, the company must still complete several administrative approval processes, including certification of the Canadian production quality system, before it can sell the product in Canada, indicating a level of uncertainty [1]